Thirty 9-14 month olds received 2 doses of PRP and 30 PRP-D intramuscularly 1 month apart in mid-1983, and were given a single dose (booster) of PRP-D 1 year later. Reactions were monitored for 24-48 hours. Sera were obtained prior to each immunization, 1 month post second dose and booster and tested for anti-PRP antibody by Farr or SPRIA techniques. Only mild local reactions, mainly erythema, were noted post booster in 25% of both groups. No febrile or systemic reactions were reported. 1 month post second dose, PRP recipients had a mean anti-PRE' concentration of 0.08 uglml which fell to 0.04 ug after 1 year. The percent with 1 uglml anti-PRP fell from 22% at 1 month post second dose to 9% at 1 year. Among PRP-D recipients, mean levels of anti-PRP fell from 4.8 uglml at 1 month post second dose to 1.2 ug at 1 year. 
Thirty 9-14 month olds received 2 doses of PRP and 30 PRP-D intramuscularly 1 month apart in mid-1983, and were given a single dose (booster) of PRP-D 1 year later. Reactions were monitored for 24-48 hours. Sera were obtained prior to each immunization, 1 month post second dose and booster and tested for anti-PRP antibody by Farr or SPRIA techniques. Only mild local reactions, mainly erythema, were noted post booster in 25% of both groups. No febrile or systemic reactions were reported. 1 month post second dose, PRP recipients had a mean anti-PRE' concentration of 0.08 uglml which fell to 0.04 ug after 1 year. The percent with 1 uglml anti-PRP fell from 22% at 1 month post second dose to 9% at 1 year. Among PRP-D recipients, mean levels of anti-PRP fell from 4.8 uglml at 1 month post second dose to 1.2 ug at 1 year.
86% had anti-PRP of 2 1 uglml 1 month post second dose compared with 59% at 1 year, but none had less than 0.15 uglml. 1 month following a booster dose of PRP-D, geometric mean anti-PRP concentrations were 8.6 and 71. Although tube feeding formulae are known to frequently be contaminated with bacteria, few cases of sepsis related to tube feedings have been reported. A premature infant admitted to the Special Care Nursery appeared to develop sepsis in this manner. She had received hyperalimentation for one month followed by enteral tube feedings of ~re~estimilR formula. One month later, she became septic; E. cloacae and X. pneumoniae were isolated from the blood. E. cloacae and P. aeruginosa were isolated from the stool. Samples of the formula, which had been distributed to the patient unit, as well as a portion which had remained in the pharmacy after mixing, were cultured and found to contain the following: E. cloacae (105 cfulml), P. aeruginosa (3-5x104 cfulml) , K. p n~u m~2 -8 x 1 0 4 cfulml) , -and A. calcoaceticus, var. antraius (-5-8x104 cfulml). Since the formula was found to be contaminated while still in the pharmacy where it had been mixed, investigations focused on the preparation of the formula. Formula had been prepared from a powder using utensils and a technique considered "clean" but not sterile. Changes were introduced to insure a 3 minute hand scrub prior to mixing, the use of sterile andlor disposable utensils, disinfection of the work areas and the mixing of formula under a laminar flow hood. Subsequent cultures of formula remained negative and no further cases were seen over the ensuing 12 months.
CATHETER-RELATED INFECTION I N INFANTS DUF T O AN
UNUSUAL LIPOPHILIC YEAST -MALASSEZIA FURFUR. John 1137 6 . Lonq, Harry L . Keyserlinq Spon. bv?Gi?JG J.-Nahmias). E m~v e r s i t y School of Medihine. Debartment of pediatrics, ~t i a n t a , GAMalassezia furfur, a lipophilic yeast of the qenus Pityrosporwn, EiES tinea versicolor and only rarely invasive infections. Retween Sept. 1983 and Auq. lq84, N furfur was isolated from blood cultures obtained during 5 episoXi-?? suspected sepsis i n 4 hospitalized infants with central venous catheters. The yeast 1rsual1.y grew slowly and was not evident in broth unless subcultured on Sabouraud's medium with s t e r i l e olive o i l . In 4 of the 5 episodes, a simultaneous huffy coat Cram stain of blood from the central catheter also demonstrated the yeast. All patients had been hospitalized since birth and were receivinq prolonged hy~eralimentation therapy, including an intravenous f a t emulsion. The infection qenerally presented as fever without focal findinqs; one afebri l e infant developed episodes of apnea and brad,ycardia. Thrombocytopenia was a prominent findinq in 3 of 4 patients. Patients responded rapidly to removal of the infected catheter and/or discontinuance of f a t therapy. Pmphot e r i c i n B was administered in three episodes. Since M furfur requires an exoqenous source of long chain f a t t y a c i d S f o r qrowth, the pathoqenic potential of t h i s yeast may be related to the introduction of intravenous f a t therapy. This yeast infection may be more comnon than heretofore appreciated. Since routine cultures mau be negative or qrowth may be poor, the use of buff,v coat Gram stains and subcultures onto lipid enriched media should help greatly in i t s recoqnition. Extrapolation from 0 to m produced similar results. Data show that acetaminophen increases plasma clearance of chloro mainly by increasing Kel (h-l) with little effect on AVd. Acetaminophen and chloramphenicol are commonly used medications. When used in combination we suggest that plasma concentrations of chloramphenicol be monitored to assure efficacy of antibiotic therapy. Exit site swelling, previous catheter repair or occlwsion were found to increase the incidence of SCVC related infection. No statistically significant differences were found in either the incidence or the location (exit site or blood) of infection in either group. The 53 pts receiving cRX exhibited a 27% (17 infect162 catheters) infection rate (13117 were bacteremic).
Kinetic Variable

DIFFERENCBS IN
There were 8.1 bacteremic episodes and 2.5 exit site infections per 100 catheter days. Similarly, the 33 non-cancer pts exhibited a 22% (9 infect140 catheters) infection rate (619 were bacteremic). These pts had 8 bacteremic episodes and 4 exit site infections per 100 catheter days. However, the organisms causing sepsis in each group were different. In children without cancer, sepsis was caused only by fungus and gram positive organisms: Staph species (50%) C. albicans (33%). enterococcus and Candida (17%). Gram negative --bacteremia occurred only in cancer pts: Gram negatives (23%), Staph species (46%), Strep (23%), Candida and S. aureus (8%).
These data demonstrate that SCVC $ a E t is associated with similar infection risks in both cancer and non-cancer pts, although the spectrum of organisms causing infection differs between the two group. WIN 51,711 is an antiviral agent with demonstrated in vitro activity against a number of Picornaviruses, including Coxsackievirus A9 (CA9). The drug has proved to be effective in animal model studies against Echovirus 9 and Poliovirus 2 infection in mice. This study used white Swiss mice which were infected with CA9 when they were between 24 and 48 hours of age. The LD50 for these mice was established as 1.8 x lo5 TCID, and this quantity of virus was injected intraperitoneally (ip).
Several routes of delivery of the drug have been tested. Giving 100 mglkglday of the drug in a 1% gum tragacanth suspension as a single daily ip injection led to significent delay in weight gain and mortality approaching 50%. Reducing this dose to 50 mglkglday ip appeared to alleviate this problem, as did delivering 100 mglkglday subcutaneously instead of ip. In the limited numbers of mice studied to date, protection against mortality using the latter two routes is 100%. Adniinistering 100 mg/kg/day po once daily in a 1% gum tragacanth suspension had no effect on animal growth, but also provided no protection against mortality or symptomatology. It is hypothesized that this lack of effect reflects either poor absorption via the po route in suckling mice, or the shorter half-life of the drug when administered in oral boluses instead of ip or subcutaneous deposition. The toxicity of the 100 rnglkglday dose ip appeared to be mechanical, since eventually crystals could be seen to accumulate in the peritoneum. Chloro Acetaminophen P
